The protective mechanism of Tao Hong Si Wu decoction against breast cancer through regulation of EGFR/ERK1/2 signaling.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier Sequoia Country of Publication: Ireland NLM ID: 7903310 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-7573 (Electronic) Linking ISSN: 03788741 NLM ISO Abbreviation: J Ethnopharmacol Subsets: MEDLINE
    • Publication Information:
      Publication: Limerick : Elsevier Sequoia
      Original Publication: Lausanne, Elsevier Sequoia.
    • Subject Terms:
      Drugs, Chinese Herbal*/pharmacology ; Breast Neoplasms*/drug therapy ; Breast Neoplasms*/pathology ; Breast Neoplasms*/metabolism ; ErbB Receptors*/metabolism ; MAP Kinase Signaling System*/drug effects ; Apoptosis*/drug effects; Female ; Animals ; Humans ; Cell Line, Tumor ; Mice, Inbred BALB C ; Cell Movement/drug effects ; Antineoplastic Agents, Phytogenic/pharmacology ; Mice ; Mice, Nude ; Xenograft Model Antitumor Assays ; MCF-7 Cells
    • Abstract:
      Ethnopharmacological Relevance: Tao Hong Si Wu Decoction (THSWD), a traditional Chinese herbal medicine, is widely utilized in clinical settings, either alone or in combination with other medications, for the treatment of breast cancer.
      Aim of the Study: The specific targeting molecule(s) of THSWD and its associated molecular mechanisms remain unclear. This research aims to elucidate the underlying molecular mechanisms of THSWD in the treatment of breast cancer.
      Materials and Methods: The pharmacological properties of THSWD were investigated in breast cancer cells and tumor tissues using a range of methods including Acridine Orange/Ethidium Bromide (AO/EB) staining, Transwell assay, flow cytometry, immunofluorescence assay, and breast cancer mice models.
      Results: Our findings demonstrate that THSWD induces necrosis and/or apoptosis in breast cancer cells, while significantly inhibiting cell migration. Target proteins of THSWD in anticancer activity include EGFR, RAS, and others. THSWD treatment for breast cancer is associated with the EGFR/ERK1/2 signaling pathway.
      Conclusion: Our findings offer initial insights into the primary mechanism of action of THSWD in breast cancer treatment, indicating its potential as a complementary therapy deserving further investigation.
      Competing Interests: Declaration of competing interest We confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.
      (Copyright © 2024 Elsevier B.V. All rights reserved.)
    • Contributed Indexing:
      Keywords: Apoptosis; Breast cancer; EGFR/ERK1/2; MMTV-PyMT; THSWD; Traditional Chinese medicine
    • Accession Number:
      0 (Drugs, Chinese Herbal)
      EC 2.7.10.1 (ErbB Receptors)
      EC 2.7.10.1 (EGFR protein, human)
      0 (Antineoplastic Agents, Phytogenic)
    • Publication Date:
      Date Created: 20240522 Date Completed: 20240611 Latest Revision: 20240621
    • Publication Date:
      20240621
    • Accession Number:
      10.1016/j.jep.2024.118339
    • Accession Number:
      38777083